COMPANY REGISTRATION NUMBER 6310215 AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE CONSOLIDATED FINANCIAL STATEMENTS 31 DECEMBER 2022 Charity Number 1121258 AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE FINANCIAL STATEMENTS YEAR ENDED 31 DECEMBER 2022 CONTETrtrs PAGE Chairman's Statement Trustees Annual Report Independent auditor's report to the members Consolidated Statement ol financial activities lincorporating the income arml eXper￿lture account) 12 Charrty Statement of financi￿ activibes (incorporating the incom& and expenditure account) 13 Consolldated Balance sheet 14 Charity Balance sheet 15 Consolidate(I Statement ol Cashllows 16 Charity Statement of Cashflows 17 Notes to thg financial 5taternents 18 AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE CHAIRMAN'S STATEMENT YEAR ENDED 31 DECEMBER 2022 As the pandemic gave way to a cost of livtng cjisis we leamed a great de￿ about the cornrnunrbes in which we live and worlL To be on the reTriving end of so much goodwill, in the rnost chall8nging of )rne5 was humbliNJ. TaI￿rg to our supporters, hearing their stories and what motivates them to go out, in all weathers, to raise funds in supwrt ol our research tearnlsl has been gafvanising. This year everyone has risen to the Ch￿Ie￿98. At the Unwersity of SoLFthaTnPton Dr Charti& &rts publishad his findings in which he identified crown like stwctures whTrch could hinder r85PDnseto trgatsnents in oveTweiqM and obese patients. His discovery of a potential biomarfler 11 be of Inte￿$t to dinitsans and researchers involved in breast cancer treatment and wuld poteniiJly be used to develop person￿lsed treaknent in patients with HE￿* overexpressed breast cancer. At Oriel College in Oxford, Senior Research Fellow Dr Sirnon Lord was gwen the honour of being guest S￿aker at the colleg8's Alumai We8kend. Already havirvJ rea¢h8d a prominent role in dinicd brea￿ eancar resèarch in Oxford, Dr Lord is expected to become a leader in clinical breast cancer research. In September our supporters were the first visitors to be invited to the Centre for Can￿r Imrnunolcgy Sin[￿ th beginnino of lrtkdown. Professor Stèphen Bèèts and hi5 tèam gave our supporters the than￿ to hear1he laiegt research news and developments befo￿ ￿ce￿n9 a chance to tour the faulty. The welcome retum offace to face- in re￿ lrfe- events was cemented for us in Septemterwith the very wekornè return of th8 Breast Wak Ever. It was wonderful to see so rnany friendly faces retuming, all contributing to make it a huge success. Thanks must go to our sponsors and leam ol vdunteers wrthout whom holding such events just would not be posslole. behdf of Ihe bDard of Irustegs l extend ourthanks to everyone invow, fortheirgenerosity. thwrtime and th8ir dedication to our cause. a futu￿ Iree from breast cancer. Rthard Bahu Chair ol Trustees AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE TRUSTEES ANNUAL REPORT (Incorporatlng the Directors, Report) (wnllnuedj YEAR ENDED 31 DECEMBER 2022 The trustees, who are ￿$ts directors for the purposes of company law, present thwr report and the finarKial statemems of the tharity lor the year ended 31 D8cember 2022. OWECTIVES AND AcnvmES Against Breast Cancer IABCI was established to fund unique research into seetsndary breast Can￿r, the mwn cause of breast-Can￿r ￿lated deaths. Tre secondary spread of breast Can￿r, or metastasis, is currentty an incunble condition which can Dccur in up lo 40Yo of breast cancer patients, sometimes years after a primary diagnosis and treatmenL which cLwms the lives of 12,000 people each year in the UK. ABC rais8 money to incrèase the survwal rates of breast cancer patients by supportlng research in 4 area5,- 11 to develop trèatments lorsecondary breast Can￿r, umirnately a va￿1n& 21 to develop tools forthe eaAier diagnosis of 58condary breast canTrr 31 to understand which diet and lif&style factors irnpact risk ol reoJrrenc8 or spread 41 to provide a platform forcommunicaiion to drive the scientrfic field forward. A8Gfounder and breast cancerresearcher Dr. Anthony Leathem disei)v8r8d a difference in the sugar archrteeiure- Ihe glyccbiology - on aggressfve brèa cancers (x)mpared lo less invasive types of breast ca￿er. Public Beneflt The Trustees confimi th* Ihey have complied Iwth the duty of section 17 01 the Charities Act 2011 to have due regard to the guidance issuèd by The Charity Commission on public benefiL The CharItsb￿ purpose forthtr tharity within the meaning ofthe Act is enshrined within its objectnies staled above. The ho￿$tiC aFprtsAch to our research Strategy exists to benefit the 600,000 p￿pIe wrrendy living with a diagnosis ot b￿ast cancer in the UK and predKted to ri58 to 1.2 million by 2030. Our research ￿lS undèrthree main themes.. Prevention. Delectron, and Thèrapy. While th& Therapeutic Aritibody programme principally fixu&%es on Therapy, our research into Prevention and Detection is complemented ty the expected establi5hrnent of the ABC &obank which Mll be closely 5ink6d to the ABC Discover programme. Prevention is focuse(l on improving our uniJerstsnding of the undedying biological arKI itnmunological mechanisrns drimng tt)e associatDn between diet, lifestyle, and breast carKer metast85iS. This understanding will better inform our approach to d8veloping novel immunolherapies and maxirni8e thelr therapeutic efficacy. Dètection, involv&% Wor￿￿9 to identify gtycan biomarkers thatwill offer noval targets for therapy. In parallel, we are eontinuino our strategy of developing novèl Herceptin derivatives through the explotlation of antibDdy engineering. As the projects in the prevention and detection theme develop these wll fe8d into the therapy theme. fvrther intorming our design approach. This strategy di9n5 Wth ouroveratl ambition to get our most promlslng iherapeut 018cule into clinical trials. We also to ev0￿& the programmèto unite exper5ment￿ immunotherapies with the longterm and on-going wo by ABC on understanL1ing the irnpacl ol Diet &1rf8styIe. Where opporDJnitie5 exist to aC￿lerate proj8cts, hoalnst Breast Ca￿T woJk% in ¢ollaboration ￿th otherfunding bodies. Results of ourlunded research proj8cts are publishe(l in Fwr-reV￿edIOur￿￿$. Detwls of all pUN￿hed papers a avalable from the charity w&Jsite. ACHIEVEMEKfs ANO PERFORMANCE The TnJstee5 prowde good governan￿ by salegLwding and promoting thg organisaiions fyputation and acting a¢cordillg to high ethic￿ standar¢8s. They ensure that Ihe charity acts in a responsible manner in attordance wth good fundrasing practice. AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE TRUSTEES ANNUAL REPORT (Incorporating the Directors, Report) fconunued) YEAR ENDED 31 DECEMBER 2022 Brobank update: Drlvixg innovation while maintalning data protectlon and ￿Urity The establishment of the ABG Biobank VAII play a pivgtal tr)le in advancirtg our ￿Search. This year we reache(I sNJnificant achlevements to enable this resourcg b) te handEd over to Professor Paul Skipp and hls team at the UnNersty of Southampton. We are confident the ABC Biobank Nwll faulilate Profèssor Sknpp ancl his team to make strides in fa(alitating groundbrethng research while maintaining data securty and compliance with ethical standards. These achievements and ongoing èttorts dèmonstrate the chartys unwavering commiknern to advancing medica] seience responsibly and securely. Toppling the crown'_Scientists dlscovera polentlal new rnarkerto personallsed thevapyfor breastcancer A new study from the Un￿ersty of Southampton has discovered that 'crown4ike structures, surrounrfing breast tumours in oven¥eighi and obese patients could hinder their response to therapy. findiros ol this study CLJuld pOtenti￿ty be used to imyove Person￿l£•d trgatrnent for patients with HER2+ overexpre5sed breast cancer. Adipose tissuè, or b(￿Y fat, is an irnportant comwnent of the hèalthy human breast and y8f high thdy mass index IBMII is assouated with increased risk of developing brea* cancer. Overwaght patients aL80 have worse survNal rates than patients wlth h&aW body weight. In patients with a high BMI, irEcreased body fat surrounding the breastcan cause inflammatory irnmune cdls, called rnacTophages, to gather in the breast's fat tissue. Trese macrophages ¢an then forrn what are called 'wwn-like structures. by surrounding thes8 fat cells (see picture below). This Creates an inflatnmatory environment in the breast which can lead io the onset and growth of turnours. How these crown-1Skè struclures go on to affect breast canc8rprogressk)n and response to therapywas prevSous largely unknown. The research team, led by Professors Stephen Beers, Ramsey Cutr8S5 and Aganst Breast Cancerfunded Lecturer Dr Chades Birts. assessed samples from a gr￿p of HER2+ breast earKer patients to investigate the link b8tween high BMI and Ihe forrnation of crown-like structures, a￿d the subsequ8nt eff8cl ofthese on how patients ￿spOndE￿ to therapy wth a dnjg caled trastuzurnab IHerceptirl&l. The results, published in the Journ￿ Scientific Reports, showed Ihat patients that were overweight or obese had signilicanlly MO￿ CTown-like structur8S in their lat tissue surrounding the turnour, and thatthis was assouated with a faster time to metastalc disease, an indleation of how well the pat'ents have responded to therapy. They then went on to klentify a PDtential molecular biomarker, cJled CD32B. on the surtace of the macrophages in these crown-like structures. Wh8n this marf(er was present in ovèrweight and obese patients, their response to trastuzurnab therapywas [￿rer. Professor Beers explai￿, Yhese ffndings wll be of interest to dinioan5 and researchers invofved in breast cancer tr8atment as they coukl potentially be used to develop p8rsonallsed treatrnent in Pthnts with HER2+ overèxpressed breast caNcer.' "For eXam￿e, doctors woukj know that patients with a high BMI and CD32B on theircrown4ike structu￿$ are I1￿elY to have a poor r8sponse totrasbJzumabtherBpy. They rnaytherefo￿ benefitfrorn more intensive8nti-HER2therapy earfier in thwr treatment. 'On Ihe other hand, this Study highligms how effective trasiuzumab treatment is in patients that do not have CD32B Posthve crown-like structures. So these patients coukl benefit froln a lower dose of &nti-HER2 therapy which may minimise the sidè-effects the experience. Further studies wth MO￿ patients wll be needed to hdp confirm these initial firKlings.' The research team are now looking at ways to change the bèhamour of these CTown-like stnjctures to improve AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE TRUSTEES ANNUAL REPORT (Incorporating the Directors. Report) (contlnu YEAR ENDED 31 DECEMBER 2022 responses to breast cancer therapy. This ￿Search has been pjblithed in the peer rwewed loum￿ scientif￿ Rep)rts. The rèsearch tearn inc1L￿e￿ Dr Constaniinos Sawa, Professor Max Grispin. Dr Ellen Copson, Dr J8remy Blaydes, Prole550r Peter Johnson, Or Stéphanre Laversin. Dr Margaret Ashton-Key. Charlty report With tsvo unprecedentsd years behiThJ us, 2022 promised to deliver a return to knndralslng Iwth a more familiar look and feel. The welcome lrfbng of restrictions allow￿ us to put into acb.on plans prepared during lockdown. We used the èbsence of to faee fundraising as an appo￿nity to hokl diffèrènt conversations th our supporters, to better understatTrd their motivation and ambitions for Ihg charity. As a resuk of these conveTSations, and in recognition of the surge tn clemand we began to receive for breast awareness and advice. we added new lools and created new resourc8$ to enable us to better meet needs of our supporters. irres￿tiVe ol age orgendeT. We continue to grow our digital presence and plan to continue on this trajectory. Our brand is TncTÈasingly recognisab18, our website and social media chanftels have been a hNe of actNty- We believe this is key to supwrtets rebJmirvJ tirne and bme again. In 2022 we had the unique opportunity to ￿eruit two London Marathon tearns for events in OciobEr aThl April 2023. Competthon for guaranteed 8ntry charity ￿a¢e$ va5 fierc8 With dernantt heavily oulstrippng supply. In Septemberwè h8kl ourfirst Breast Walk Ever for3 years, with 3 brand new ircular rou18s, W￿kerS were treated to nearperfect walking conditions. We also entered teams into the Berlin Marathon and London to Brighton CYC￿ ridè. Our Play it Pink campaign proved popular 5POrts dubs. team England hockey ￿aYer Sarn Ward jointy raised over£701K> together wrth his local tsam in Bishops Stortford. Locally. our first In-[￿rsOn event was to fu￿1 a commibnent made in 2019 to the Harwell Women's Institute. The group has been supporting the charity since the beginning. Annual events Splash of Pink aNd Witney in the Pink retumed, a￿ayS popular, they each provide great Opportun￿9$ to mwntain our protila in Oxfordshire and PTOVkYe an important SOUT￿ ol funds. We welcomed a new ind8peThJent fundrnsing group Charity AngeLs, pledg6d to fund Sirnon Lord's Tesearth project lor onè y9ar at the Universty of Oxford. The number of companies supp)rting us continues to grow, Part￿￿larty through the month of October. B￿ast Cancer Awareness Month. This support takes many lorms. from pink products and packaging to In-house fundraising and sponsorship. No matterthe s&e of Ihe cornpany, weare grateful to thern fortheir$uppDrt. Dishmatic return8d for another year with 8 £10,000 donation and brand awareness carnpalgn. This year Natracare ￿s0 supported a generous (*)nation of£10,000 and bespoke product packaging based on the chan"ty's brand. W8 created our Spring and Auturnn Together n8wslett&r8 shouting thut tsur amazing supporter5, thanknng them for ￿1 they do and ukyjating them on our ￿Search and u￿orning events. Oth8r supporters hekl Breast Tea ever eYerEts. raff￿, quiz nigms alld much More. We saw manytribjie pages set up in memorywrth our partners MuchLoved.com. We aL80 partnered wlth Guardian Angel a free will writing service. We were able to hold ourfirst open day forthree years atthe University of Southampton. Led by Professor Stephen Beers, supporters attended presentaiions, toured the facility and had a chance to rrteet membets of the research team to learn morè about the latest developments in our re￿arCh. (Ajr doorstep dothes r8cyding scherne was parriojlarly affect￿ by the war in EuTope, Ukraine being a key AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE TRUSTEES ANNUAL REPORT (Incorporating the Directors, Report) (contlnuL YEAR ENDED 31 DECEMBER 2022 destinaton for rnary of the it@lls donated. Despte this setback. inrxyne generated irnproved over the year as ngw collecting teams were introclucEd. Income from our Ink and Toner Fiecycling scheme was subject to the re(Juction in many offic88 and places of work b8ing used during the pandernic. We anticipate this improving as the workforc8 returro to places of woth. Our bra recycling s¢heme and ne￿tsth of bra knks remaSns strongwth almost 800 bcations listed on the webstte. wilh demand remaining hvJh, we expect this to continue to grow. E-commerce $￿e$ revenue from our online shop showed aSteadygrO￿. Plans to continue to develop this further are in place. FINANCIAL REVIEW Against Breast Cancer made a profit of1£17,5521 in 2022 comparwj to a loss 011£156,9181 in 2021. Consolidated inwme for 2022 was £875,116 compared to £754,767 in 2021. Income was for a third year dramatirally impacted but showed a marked increase in funds indicating that we are entering into a rnore stable peric¥J. As w8 move into 2023 there i8 a delinrfte uplift in fundraigng wih evèrrts now back to amost a pre pandern￿ level. Edging closerto bringing us back in line ￿th the 5-year income grobvth strategy of 2019 with the intention of in¢￿asIng incDme to £1.5 million overthe next ￿uPle of years. Followng the funded research ol the DietCom￿y[ st￿Y at the Unwer5ity of Westminster in 2015 the chatity developed a research strategy funding long term and short-ierrn innovatwe research prolects. In addition to our loNJ terrn cor8 research we also fund PhD's and Junior Research Fellowships tor the advancernent ot education through teaching and research. These projects are funded responsibly in line with Agwnst Breast Cancers objectives, and surplus funds ring fenced annualy for further spend on researth projects and lab equipment. The re58arch strategy and charity long terrn projections See responsible, sustainable and Substanti￿ growvth in funding in llne with projèct8d growth in income and maximising ROI. Against Breast Cancer continues to work ￿th the clinical 4)onsor ot thè D]'etCompLyf sludy, University College London, to pirt pro￿$se$ in place to make the data and samples from the DietCompLyf available for further search. Against Breast Can￿r ha5 a projected long-term res8arch portfolio in excèss of £4million. This portfolio has been steadily built in line wiEh the ie58arch strategy arKI eharity long term projections 8nsuriry sustainabiltty for the future. PLANS FOR FUTURE PERIODS Looking forward to 2023 we have already recruitsd the largest nurnber of overseas events partiupants the eharEty has ever assembled. We plan to contlnue with the improve the quality aThJ frequency ol ourcommunications. We wll introduce a new WalkEv8r. Iwated nearsouthampton. rtwll be an oppjrtunityto growourreputstion and supporter base in Hampshlre. We are looknng lo dEverwfy our income strèarn5 as we inveslgate the wortd ol online garning and streaming further. We ￿an to continue the incr8a5e of marcomms bth a150 who wg send what to a￿d in what medum. we will introduce SMS rnath&hrvJ and analyse ow rates. We will focus on our cotporate fundraising. Companies are On￿ again opening up their charity partnerships after Covid and many are open to have conversations regardirKJ their charit*e lunding. REGULATORY COMPLIANCE Trustees continueto play an active rtsle inthe administration ofthe charity. ensuring we areattountableto everyone with an inter9sL They ensure the ch2rity's resources are managed resrx)n$ibty and in accordance with current legislth"on. The trustees abide by both thè Code of Fundraising PraCt￿e and the Charty Governan￿ C¢xle to ensura b8St possitle practice in their g0verllan￿ of the charity- AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE TRUSTEES ANNUAL REPORT (Incorporating the Directors, Report) f¢onUnuedJ YEAR ENDED 31 DECEMBER 2022 STrUCTURE, GOVERNANCE AND MANAGEMENT Governing Docurnent Agansl B￿a$1 Cancer ￿rnited is a company limited by guarantee and regist*r8d gs a thartty. Thg govgming document of the charity is the Mernorandum and Art￿leS olAssociation issued 11 Juty 2007. Governlng Body C￿eTaIl responslbilty r8sts with the Board of Trustees bvho are aLso a4¥ointed as directors of th& charitable company. Authorty Irom the Trustees is del8gatsd to the Chief Executive ICEOI, Bemadette Jones, who is Tesponslble for the day to day managernent ol the ehartys aff&rs and forthe implementation of policies agreed by the board. The CEO is assisted by a management team, Siaff and volunteers. board appToves the delegaivjn of financi authority through the CEO, with spe¢thc limits irnFX)sed within an approved scheme of delegation. RecruitmenL Appointment. and Trdining of Twst*s The appointment of Trttstees i8 rnade in aLrordance with the Arbcles ofAssociation hvhich includes the recèipt and approval of an appli¢alion lor rnembership. The s8lect￿n of Trustees is designed to supplement the existing skills and expertise of the Board arKI is govemed by an Infornial sknlls assessmenl. Thè Twstees recognise that a more forma approach shoufd be taken in respect of theii inductK)n and training, particularly as regards to new appointrnents, and procedures are belng fDrffiulated this yeaT. This includes the declaration ol eligibility to serve as a Trustee includiro notification of any potential conflicts of interest. Currenoy Against Breast Can￿r Umited has eight trustees. Together they provide a broad range of s￿11$ and eyrtise Ihat tre trustees want represented to ensure a sirong board - these include scientific and medical bad(grounds. strategic thinking, fina￿la1 and organisational management and marteting skills. In addition, many ol the trustees have persond exp8rien¢e of the Impact of breast caneer on peDples' live5 and so are ernpathetrc towards the goals of the charity. Organlsattonol Management The trustees have leg￿ reswnsibility for the Strateg￿ direction and effectNe governan￿ of the charity. The tDJstees, dso beirg ￿1￿CtorS of the company, who selved duriThJ 2020 are listed on p*g8 8. On average Ihe board rn8ets fourtime5 a year. Group Structure and Relationships Th8 charity has awholly ownal subsidiary. Against Breast CarKer (Trading) ￿mItert, registerèd in England number 8310215. The sut6idiary orErates from premises leased by the tharitable company and sells prornotional items bearin9 the Against breast Can￿r logo. ￿ donates its taxable profits to the charitable company. Against Breast Cancer achiev88 its objectNe of commissionlng research through rts close relationship with a research team based at Unpiersty of Southampton, and a research team based at the Universty ol Oxford. The charity promdes a grant to each t8arn which funds ihelr salary and laboratory and enables th8 or¥Joing ￿SearCh to take pla￿. Ag&llst Breast Cancer also established a Fellowship programme in 2014, to support rising scientific talent in the b￿ast cancer research Ileld. The first 3-year Fellowship i8 associated wth Oriel College, Oxford. and was award£d to Dr. Max Crispin who is designing newtreatrxents for metastabc b￿ast cancer. Following on from this Fellowship. in 2018 Aganst Breast Cancer wth Oriel College s&t up a 9 year ABC funded Junior Fellowship programme to continue advancements of education through t8aching and research. Reseryes Policy Agwnst Breast Cèneer decided on a p)licy of holdiNJ 3 to 6 months operating costs. A ligure of £150.000 was considered to be a ￿aSOnable level of ￿erVeS to be held that woukj enable the charty to meet all of its liabilities should operations have to cease at sorne polnt in the futu￿. This includes costs such as redundancy lor ernployees, professiond fees and a wind down ol thp re583rth programmè. AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE TRUSTEES ANNUAL REPORT (Incorporaling the Directors, Report) (contlnued) YEAR ENDED 31 DECEMBER 2022 A5 at the 31st Dpcember 2022 the charity held total reserves of £417.197. of this amount £10.000 was held as restricted. Risk Management The major risks, to which the charty is exposed, as k%enbffed by thè Trustees, have been rewewed and systems have been established to miligate those risks. REFERENCE AND ADMINISTRATIVE D￿AlLs Reg[￿er￿ charlty name Against Breast Cancer knmitEd Charlty reglstraiion nurnber 1121258 Company regislration nurn￿r S310215 Registered office Leathem Houso 13 Napier Court Barton Lane Abingdon Oxon OX14 3 The trustees The trustees who sekved the charity dL¥riro the were as folIows: Mrs J Chattoe Mis5 V Harmer Miss N A L Webb Mr R Bahu Mrs L HoJnam Mr5 J Collins Mr D Remoundas Audittir David Cadwallader & Co ￿mited Chartered Certified Accountants & Statutory Auditor Suite 3 Bignell Park Bams Chesterton Nr Bicester Oxon OX26 1TD AUDITOR David Cadwallader & Co timited are deemedlo be rtrappointed U￿er section 487121 of the Cornpanies Act 20C6. TRUSTEES, RESPONSIBIUTIES STATEM The trustees (who a￿ aL%o Ih8 directors of Against Br8ast Can￿r knrnitgj for the purposes of eompary lawl a responsibl& for preparing the TrLSt88s Annual Report and the financial statements in accordance wth ap￿￿able law and regulations. Cornpany requires the trustees lo prepare linarriai stat8rnents for each financia year. Under that law the AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE TRUSTEES ANNUAL REPORT (Incorporating the Directors, Report) (conttnued) YEAR ENDED 31 DECEMBER 2022 twstee5 have electeol to yepare the finanlxal statèrnents in arK0rda￿e United ￿n9￿orn Generally Accepted Accounting Practice (United ￿ngdoM A(xounting Standards and applicable lawl. Under cornpany law the trustees musi not approv8 th8 finaN¢ial statements unless they a￿ ￿l$flo￿ thal they g￿8 a true and fair view of tre slate of affairs ol the charfty aThJ the income and 8xpenditure of the charity for that perii)d. In preparing thes8 financial staternents, the trustees are ￿Uir￿j to-. select SUita￿e aecounting policies and Ih8n apply them congstentty., observe the methods and principles in the Charities SORP.. rnak8 judgements and aco)untlng estimates that are r8asonable and prudent., and prepa￿ the fInar￿1￿ statements on the going concem basis unless it is inaFpropriate to presume that the charity wlll continue in operation. The trustees are responsible for keeping adequate accounting records that are sufficient to show and eX￿an t chantys transactions and disdose with reasonable accuracy at any tim8 th8 finan￿al posthon of the charty ar¥J enable them io ensUrethatIhefinan￿aI statements complywiththe Companies Act2006. They arealso responsib for safeguarding the assets of the charty and hence for takmg reasonable steps for thè prevention and d￿t￿tion of fraud and olher irregularities. STATEMENT AS TO DISCLOSURE OF INFORMATION TO THE AUDITOR Eath of thè p8rsons who is a trustee atthe dale ot approval of this report confirms that.. so faras eaeh trustee is aware. there is no relevant audlt infomiation of whichthe charitys aLLlitor is unaware: and each trustee has taken all steps that they ought to have taken as a trustee to make themself awarè of 8ny relevant audit information and to establsh that the charitys auditor is aware of that information. SMALL COMPANY PROVISIONS Thi5 fEpDrt has ￿8n prepared in acCortjan￿ wth thè wovisions applicable to compaffj&s entrlled to the smaIl companies exemoion. Regi518red office= Leathem House 13 Napier Court Barton Lane Abingdon Oxon OX14 3Yf Signed by orderol the trusteeg R Bahu Trustee Dlrector 8 September 2023 AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF AGAINST BREAST CANCER GROUP LIMITED foonlinl￿￿? YEAR ENDED 31 DECEMBER 2022 OPINION We have audited the 1(naniial statements of Against B￿aSt Cancer Limited Ithe'Parent Charitable Company) and its subsidiaries Ithe'Group'l for the year ended 31 De￿mber 2022 on pages 12 to 26 which cornprise the Group Statement ol Financi￿ Activities, the Group Sumrnary Income and Expenditure Acwunt. the Group and the Parent Charitable Company Balance Sheet, the Group and the Parent Charitable Company Cash Flow Statefflent and related notes, iwluding a summary of signifleant accounting poliues. The finall￿￿1 reporting framework that has bèen applied in their preparation 15 applicable law and United Kingdom Accounting Standards (Unita Kingdom Generally Accepted Accounting Practi￿) including FRS 102 "The Financial Repoiting Standard applicable in the UK and Republic of Ireland" In our opinion-. the flnancid statements give a tnje fair view ol the statè of the Group's and Parent Charrtab1e Company's affaiTS as at 31 Decernber 2022 and of the Group's and Parent Chanty's incoming resources and ap￿1¢a￿.Dn of resources, including its income and expenoiiure. forth8 yearthen end￿.. the financid statements have been property prepared In accordance w&th Unlted Kingdotn Gener￿ty Accèpted Acg)unting Practi￿. the financHI statemènts have been prepared in ac(x)Tdance wth the Companies Act 2￿)6. an¢J the Charibes Act 2011- BASIS FOR OPINION We conducted our audr( in accordance with IntÈrnationJ Standards on A￿d￿n9 (UK) IISA5 (UK)) and applicab law. Our ￿SpOnSibl4rt1eS underthosE slandards are further described in th8 Auditorfs responsibilitie5 ft)rthe audit of the financi￿ statements S￿lI0n of our report. We are independent of the group 8nd parent ¢haritable company in a¢o)rdance wth th& ethical requirements that are relevant to our audit of the financial statements in the LIK. including the FRC'S Ethic￿ Standard, and we have fulfilled our other ethical responsibilthe5 In accordance with these requirements. We belleve thar the audit 8wdence we have obta'ngd is sufficient and appropriate to proV￿le a basis for our osynion. CONCLUSIONS RELATING TO GOING CONCERN In auditing the ffnanoal ststèments, we have conduded that the tnJstees' use of the going concem basis of accounth.ng in Ihe preparation of the financi￿ statements is appropriate. Based on the worf( we have ￿rfQnned, we have not identified any material uncertainties relating to 8venl$ or con￿￿OnS th*, Individu￿lY or co118Ctniely, may cast significant doubt on the Group'$ or Parent Charitabla Company'5 ability to continue as a going concem for a perK)d of at least months from when the financval statements are auth0ris8d for issue. Our r8sponsitililies and the rfysponsiblities of the trustees with resm to going concem a￿ described in the relevant sections of this report. OTHER INFORMATION The other informalon cornpri￿$ the inlomiation ir¢lud8d in the tsustees. annu￿ report. other than the finarriaI statemetts and our auditorfs report thereon. The trustees ar8 responsible for the oth8r information contaned within the ann￿￿ reporL Our opinion on the finanoal statemeNS does not cover the other inforrnation and. except to the extent otherwise expli¢iJy stated In our report, w8 do not express any torm of assurance conclusion thereon. In Connection wilh our audit of the financi& 5tstements, our responsibility is to read the other inforrnation and, in doing so, consider whether the other infolrnation is malerfajly inconsistent wth the financial statements or our knowledge obtained in the audit or otherwse appears to be matèrially misstated. If we identity such material inconsistencies or apparent material misstat8rn&nts. we are required to deterrnine whether the￿ is a material misstaternenl in Ihe financial statements or a material misstatement of the other inforrnalion_ If, based on the work we have performed. y￿ condude that there a Mater1￿ misstaterneni of this oth8r inforrnation,. we are required to rt that fact We have nothing to retxjrt in Ihis regard. AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF AGAINST BREAST CANCER GROUP LIMITED (confin￿￿} YEAR ENDED 31 DECEMBER 2022 OPINION ON OTHER MATTER PRESCHIBED B Y THE COMPANIES ACT 2006 In our oplnion based on Ihe wort( undertaken in the course of the audlt: the informabon given In the TnJstees Annud Report lincorrorating the directors, ￿pOrt} for the financial year forwhich the frnancial statern￿ts are prepar￿ is consistent wth the finan￿al 5tat8m8nts the directors, ￿port has been prepared in aCCordar￿e with applicable legal requiremenls. MATfERS ON IVHICH WE ARE REQUIRED TO REPORT BY EXCEPTION In the light of our knowledge and understanding olthe Group antj Parent Charitable Cornpany and ts Ènvironrrent obtangd in the course of the audiL we have not identified material misstatements in the dirEctor5' reporL We h&ve nDthing to report in respect ol the following matters Whe￿ the Companies Act 2006 and the Charities Act 2011 requires us to rgport to you if, in our (yinion.. The Parent Charitable cO￿tpanY has not kept adequate and suffident accounting rseords, or r8tum5 adgquato for our audit have rsol been recewed from branches not visited by us., or The Parent Charitabfe Company financ1￿ statements are not in agreement with the accounting Tecords and retUTns- or Certain disck)sures of director5, rernUnerat￿n specffied by kw are not rnade,. or WÈ havt not rec8wed dl the information and explanations we require for our autht,. or The Trustees were not entitled to prÈpaTe the ffinanCI￿ slaternents in accordan￿ with small companies regime and take advantsge ol the 5rnall companies ex&mption from the requirernent to prep￿ a directors, report and strategic report RESPONSIBILITIES OF TRLISTEES As pxplwned more fully in the trustees. responsibil￿"eS statement IsetOLrt on pages 8-91. the truste8s Iwho are also thedirectorsofthe Parentcharitsble Company forthe puwses ofcompany lawl are responsibleforthe preparation of the financial statements and for being satisfied that they give a true and far wew, and lor such internal control as the trustees detemiine is ne￿$sary to enable the prepar8tion of financial statsrnents that are free trom material rntsstaternent. whether due to fraud or error. In preparing the financid statements, the trustses are Tesponsible for assessing the GTOUP'S arKI Parent Chariiable Company's ability to continue as a going concern, disdosing. as applicable, matters related to going conTrm and using the going con￿rn basis of accounting unless the trustees either intend to liquidate the Group or the Parent Charitable Company or to cease operations. or have no redi8tic altemab.ve but to do so. AUDITOR'S RESPONSIBILITIES FOR THE AUDIT OF THE FINANCIAL STATEMEKrs We have bEen appointed as auditor under section 151 Charfues Act 2011 and under the Companies Act 2006 and report in ac£Ordan￿ with regulations madè under those Acts. ()Jr objethes are to obt￿n r8asonabl8 assuranc8 th7Ut whether the financial slatemenls as a whole are free fmrn material misstatetn8nt. whether du8 to fraud or error. and to issue an auditor's Teport that includes our opinion. Reasonable assurance is a high level of assurance. bLrt is not a guararrtee that an audfL Conducted in acmrdance with ISAS (UK) will a￿ayS detect a materlai missiatement when it exists. Misstaiaments can arise from fraud or error and are considered matsrial if, individudly or in the aggregate, they Could ￿asOnablY be expected to influence the ecommic decisions of Ltsers taken on the basi8 of these finan¢ial statements. Irregularilès, including fraud, arè instan¢es of non-compliance wth laws and regulatirns. We design procedures in line with our responsibilities, ouifined above, to d8tect material rnisstatÈm8nts in respect of irregularities, including fraud. The extent to whth our procedures are capable of deteeting irregularites. including fraud is d￿t￿le￿ below. AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF AGAINST BREAST CANCER GROUP LIMITED (¢onllnu YEAR ENDED 31 DECEMBER 2022 We obtwned an understanding of the legal and rggulatory frameworts that are applicable to the entty and detennined that the most signfficani are those that relate to the Charibes SORP, Charthes Act 2011, Companies Act 2006, Code of FUndr￿Sir9 Practice and data protection laws (ir￿lUding UKGeneral Data Protection Regulation IGDPRII. W8 aS￿￿ed the risks of material misstatèrnenl in rgspgGt of fraud by Making enquiries of management and those charged with Govemar¢e Revi?wing fraud risk factors within discus*on of related party relationsh￿1$ and transactions B&8ed on the resulls of cur risk as5essmentwe desMJned our audit proce(*Jres to identfy non-wmpliancewith such laws and regulations identified aLKwe. The Group's and Pa￿nt Charitable Company's polirjes and procedures lor eomplian¢e ￿th those laws and regulation5 was obtained and dtscussed wth managemenL Wg oorroborated our enquiThe8 through review ol board meetlng minul&s and r8ports. No contradictory ewden was identified. We consvjered the risk offraud through management ovèrrid8 and. in response. we incorporaied testing of rnanu joumal entries throughout the year and a￿OUnting estimates atth8 yearend into our audit approach. Based on tha results of our risk assesstnent we designed our audit proCedu￿S to identity and to address material misslatemerns n relation to fraud includin9 a Teview (rf the awounb'ng p)lirAes ad¢)pted by the Group and Parent Chatitable Company particularly in relation to the recognition of incorne. We have considered the e￿ent to which the aLtclit was consKlered capable of detecting itTegularities hvhich inh8rently difficultwhen dealing with inrxjming Tesources frorn donation5. The Pargnt Charitable Company's intem8E control proc8dures have been desKJnEd to mitigate against this risL 8ecause of the inherent limitations of an audit, the￿ ES a risk thatwe will not detect [r￿ularitieS, including tho8e 18ading to a materia misstatetnent in the finanoal siaiements or nonvi5ions Creditots and provision are recognE8d where the charity has a present obligation resulting from a past event that will probably resu￿ in the transfer ot funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Credrtors ancl provisions are nomdty r8cognised at thelr semèment amount after dk)wing for any tra¢Je (Jlscounts due. Pensions The Group operate5 adefined contribuiK)n pension scheme. Contributions a￿ charged in the profit and b58 account as they become payable in ac¢ordance with rules ol the scherne. Operatlng Leases Rentals payable undèr operating leases are charged in the profil and kjss account on a straight line basis over the lease tem). Investment pollcy In the Charity balance sheet the investment in the trading subsKliary is stated at COSL AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 31 DECEMBER 2022 VOLUNTARY INCOME Group 2022 Charity 2022 Group 2021 Charity 2021 Donations Donations, grants and gifts Trust income Sporting events Gift Aid reclwmed t)onation trorn subsidiary Government Grant IrE¢ome Job Fletèntion &herne Legacies L8gacies 411.004 4.800 153.398 21,784 411.004 4,BOO 153,398 21,784 165,400 286,244 8,850 101,517 21,299 286,244 8,850 101,517 21,299 189,679 44,513 44,513 33,243 33,243 16.209 16,209 624,229 789,629 478,632 668,311 2022 irtome includes restricted grants totalling £187,963. 21)21 I￿orne includes restricted donations tot￿ling £103,163.. Donation income irKlu¢Yes £Nil12021.. £Nill in Tespect of gffts in knnd donated to the Charity. INCOMING RESOURCES FROM AcnvmES FOR GENERATING FUNDS Group 22 Chartty 2022 Group 2021 Charity 2021 Recycling income TradirKJ irtorne of subsidHry 2￿23 247,677 2,6fJ 6,544 287,858 250AOO 2,623 274,400 All income is unrestrthd lor tK)th year5. OTHER INVESTM￿ INCOME Group 2022 Charity 2W22 Group 2021 Charty 2021 Bank interest ￿CeIVable 587 1,ns 1,735 All I￿orne is unrestricted for t<>th years. OTHER INCOME Group 2022 Chaklty 2022 Group 2021 Charity 2021 Management charge frorn subsKliary l iRcom8 is unrestricted lor tx)th years. 65.000 65,000 AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 31 DECEMBER 2022 COSTS OF GENERATING VOLUNTARY INCOME Group 2022 Charty 2022 Group Charity 2021 Donations Event Fundraisir Trading costs of subsidlary Support costs 106.740 202,061 12.810 200.785 106,740 202,061 87,642 219,747 8.263 204.178 87,642 219,747 200,785 204,178 522A96 509,586 519,830 S11,587 l exper￿l￿re 15 unrestricted for both y8ars. COSTS OF CHARITABLE ACTivmES BY FUND TYPE Group 2022 Charity 2022 Group 2021 Charity 2021 Research 390,138 390.138 372.511 372.513 Grants of £n51 were pwd to indiwduak in the year to support research12021.. £nill. 2022 expendtlurg indudes resthcted costs totalling £187,963. 2021 èxp8nditure indudes restr￿e0 costs totalling £103,163. COSTS OF CHAR￿ABLE ACTIVMES BY ACTivrrYTYPE Voluntary Fundraislng Event Fundraislng Support Total 2022 Total 2021 Wages & 581arigs Employers Nl Staff Pension Staff recruitment & irainin Rates & water ght & heat Insurance Telephone Depreciation Siatsonery Publicity Event managernent Database costs Travel Propety rep￿rS & mwnlenance Ag8ncy fees online owing Miscellaneous Office equipment & hardware Postage 181,TJ1 11.792 135,836 14.0$2 6,750 6,936 4,023 786 317,567 342,558 25,610 18,878 6,160 6,562 2,230 5,011 6.003 1,600 11.118 5,168 88,950 38,879 154 2,561 15.289 13,872 &046 1,572 5,307 7.620 726 12.275 6P13 42,714 41147 166 6,936 1,609 314 1,061 3,048 290 4.910 4.494 12.814 2,414 472 1.592 3,810 363 6,138 2,419 29,900 762 1227 44.147 17 66 140 200 333 4.461 167 3,677 2.231 1.785 Charty expenditurè 52,196 239,515 217.875 509,586 511,567 Trading purchases 12,810 12,610 8,263 Group expenditu 65,006 239￿15 217WS 521396 519,830 2022 expenditure includes r8sfri¢ted costs tot￿lIng£187,9G3. 2021 exp9nditure indudes restrtiedwsts tot￿lIng £103.163 AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 31 DECEMBER 2022 OTHER COSTS Group Charity 2022 Group 2021 charity 2021 EmployeTS NIC Accountancy fees Audlt fee5 Legal fees Interest payable corporation Tax charge for year Other finanoal costs 15.0Th)) 15.OthJl 14,0001 14,0001 12.725 1.013 4222 10.050 1,013 10,839 5,831 3.478 8,389 5.831 3,478 4461 15,421 669 3,196 730 10,954 19,344 14,428 Al expenditure is unrestrittted for both yeats. 10. NET INCOMING RESOURCES FOR THE YEAR is stated after charging: Group 2022 2021 Staff ￿nSIOn contributions Depre￿atiOn Auditors, remuneration- - audit ol the finanrial statements 18,065 1.601 12.725 10.839 Chartty 2022 2021 Stalf pension contrbLrtions Depreciation Auditors, rernuneralion- - audit ol the financiJ statements 18,065 1.601 726 10,050 8,389 11. STAFF COSTS AND EMOLUMEi¥rs Total staff costs were as follows: 2022 2021 Wag85 and salaries Social security costs Other pension costs Fie(lundancy and temiinat¥)n payments 319,312 25,996 15,439 366.803 27,668 18.065 360,747 412.036 Particulars of eTnployee$: Th8 average number of employees duri￿ the year. on the bags of fulktime equ1v￿ents, was as follows= 2022 2021 No No 16 16 Numberof support staff No employee received r8Tnuneration of more than £60,000 durfng the year12021 - Nall. No Trustees were remunerated durin9 the year under review12021 - Nil) AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE NOTES TO THE FINANCIAL STATEMETrtrs YEAR ENDED 31 DECEMBER 2022 12. TAXATION- GROUP In respect of the year 2022 2021 Taxaton based on results for Ihg year 13. I￿ANGIBLE FIXED ASSEfs- GROUP AND CHARITY Patent COST At 1 January 2022 and 31 December 2￿2 1762 AMORTISATION At 1 January 2022 and 31 December 2022 2.761 NET BOOK VALUE At 31 December 2022 At 31 Oecernber 2021 14. TANGIBLE FIXED ASSETS- GROUP AND CHARITY Freehold property Equipment Total COST At l January 2022 Additions 307,782 39.009 346,791 At 31 December 2022 307.782 39,009 346.791 DEPRECIATION At 1 January 2022 Charge for the yèar At 31 December 2tr22 36,831 726 38,831 726 37,557 37,557 BOOK VALUE At 31 De￿mber 2022 307.7tr2 IA52 309.234 At 31 Deeembar 2021 307.782 2,178 309,980 15. INVESTMENTS COST Al 1 January 2022 and 31 D￿mber 2022 NET BOOK VALUE At 31 December 2021 and 31 08cernber 2022 County of ncorporation Holding Propotlon of voting rKJhts ar)d shares held Subsidlary undertaklng Against Breast Cancer Trading mrted Eroland Ordinary share 100% The investrnent rep￿sents the cx)st of lo￿ of the share capi￿ of Agalnst Breast Can¢9r Trading Limited, a company incorporaled in ErKJland and Waes. AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 31 DECEMBER 2022 16. STOCKS 2022 2021 Stock 18,022 16.066 17. DEBTORS Group 2022 Charlty 2022 Group 2021 Charity 2021 Trade debtors Amourns owed by group undertakings Other debtors Prepayments 1,461 46,483 22,665 30,904 140.250 140.250 105,337 105.337 167,096 188,194 128.002 136,241 18. CRED￿ORS. Amounts falling due within one year Group 2022 Charlty 2022 Group 2021 Charity 2021 Bank loans and over¢Jrdtt Trade creditors Arnounts owed to group undertakings Corporation Tax Taxation and socid securEty Other creditors Accruals 64303 4,098 4.075 20.no 7,182 379 20.446 5,082 285,558 6.736 407 285,558 92.142 177,534 160,090 315,184 296,776 19. CREDITORS: Amounts falling due after more than one year Group 2022 Charity 2022 Group 2021 Charity 2021 Attruds 98,437 98,437 98.437 98,437 20. Analysis of cash and cash equivalerrts Group 2022 Charity 2tr22 Group 2021 ch￿Tty 2021 Cash In Hand 21. Analysis of changes in net debt {Consolidaled cash flow statement) Balance at 1 Cash Hows January 2W2 Balance at 31 December 21722 Cash and Cash equivalents Loans due 1 year Loans atter 1 year 260,800 161,9841 198.816 Totsl 260,8(KI 161,9841 198,816 AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE NOTES TO THE FINANCIAL sTATEmE￿rs YEAR ENDED 31 DECEMBER 2022 22. Analysis ol changes in net debt (Charity cash flow statoment) atance at 1 January W22 Cash Balance at 31 Deetmber2022 CaslT and Cash 8WNalonts Loan$ due withln 1 year Loarns after 1 year 250,217 (71,9241 178393 Totsl 250.217 C11.9241 174293 23. RESThICTED INCOME FLWDS Balan¢t * 1 Janyary2022 Balgnce at Expendllure 31 Dec 2022 In¢orne Stewarts Law Foundatson The Wrfical Flesoarth Gounc 10,000 10,orK) 187.963 1187,Wl 1187,9631 10.000 187,963 10,000 stewarts Law Foundatlon Stpwarts Law Foundation granted Aganst B￿astCanCer210,0QottrfUlIy¢ata1QgU6Ih6bIo0d&UrinE samples collectsd during our 5 year c&nIC￿ trial- DvalComLyf. Tha Coll￿tiOn k th8 larggst resource ot tt8 klnd in tho UK and took approximately 16 year510 collect The Medlcal Resekrch Councll The Medical Research Counal repeated their fuTh1ing SUPPDrt ag￿￿ In 2022 to fvelp sustah earfy*areer earthers currenvy supported by medical research chariU8s. Thi5 SUPPOrt, from thÈ Department of Business. Enèrgy and Industrial Strategy IBEISI and Ihe DÉpartmentof Health and Sotyal Care IDHSCI, was In recognthon of th8 Ioss8s the research Sector suffe￿1 as a re8utt of Cowd-19. The r￿u￿Thg 'Medic REsearch char￿e8 E2rfy Career Researthers Support Fund. *mÈd to support and sustain charity-lund res8archers earfy on in their career. Thi¥ included PhD siudeni$ and thos8 With less than 10 years research exp8rlerte p05t-PhD. As a member of the AMFIC, Agalnst Breast C8ncer were elrgible lo once agan 3ppIy for this Supportand coukl nojninate up lo 10 researeher5 thalwe funded during the 202212023 financi￿ year. The successful appliration forthis&gni1￿antgrdnt funding wasvitalto the finances DI Against Breast Cancer and Wds rnL￿h appretsated bythe tnJs*. 24. UNRESTrICTED INCOME FUNDS Balance at l Janu8ry2022 Incomlryj resourtes i￿goIng Balance at 31 resources December 2022 Group Generd Funds Chality fjeneral Funds 389,645 n1,028 713.751 (n3A761 1fj56,1991 407,197 407,197 25. ANALYSJS OF ASSETS BETWEEN FUNDS CUTh8nt Tanglbl¢ asse xed assets Illab51￿￿$) Long Terni Llabllttle$ IntsNJlble ftxed assèts Toial Group Unw51rfcled F￿￿$ 309,234 16,3041 302,931 AGAINST BREAST CANCER LIMITED COMPANY LIMITED BY GUARANTEE NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 31 DECEMBER 2022 Charity Unrestrl¢ted Income Fund5 309,236 16,3061 302,931 Group Restricted Incorne Funds 10,000 10,000 Charlty Restricted Income Funds 10.000 10.0(K> 26. RELATED PARTY TRANSACTIONS At 31st DecernLEr 2022 the Charty was owed £46,48312021: £80,S¥)41 by its 10(Vo owned subsidiary, Aganst Breast Cancer Trading Lirnit8d as a result ol trade charges, and charity income received by the subsidiary less expenditur8 incurred on the subsidiarys beham. 27. COMPANY UMrrED BY GUARANTEE The Company is limited by guarantee with no issued share captta]. There is no ultimate controlling paty. 28. CAprrAL COMMrrMENTS At 31 Decembèr 2022 the Company had the authorised C4Dital commitments lot￿lIng £Nil12021: £￿111. 29. LEASING COMIAITMEpirs Minimum lease payments under non-cancellable operating leases fall due as follows:. 2022 2021 Within tsne year Be￿een one and live years Over 5 years 7,153 2.385 7,153 9,538 9,538 16,691